Artificial intelligence has now been used to create a “fundamental recent vaccine technology” that might protect against large swathes of viruses and forestall pandemics, in keeping with researchers.
A team on the University of Cambridge says that is the primary time that a vaccine whose energetic component was “designed entirely by computer simulations has been tested in humans.”
The vaccine was designed to “provide protection against multiple Sarbeco coronaviruses – the big group of viruses that occur in nature including SARS-CoV-2, which caused the COVID pandemic,” in keeping with a University of Cambridge press release.
Results from the trials published within the Journal of Infection state that the research, conducted between December 2021 and September 2023, involved 39 healthy volunteers between the ages of 18 and 50.
Get weekly health news
Receive the newest medical news and health information delivered to you each Sunday.
The vaccine “triggered immune responses within the volunteers not only to SARS-CoV-2 and SARS, but to related bat viruses that might potentially jump from animals to humans and cause future pandemics. ”
“The super antigen is compatible with most vaccine delivery systems,” the press release reads.
“On this trial it was administered as DNA vaccine through a micro fluid jet. This needle-free delivery method offers an alternative choice to those with a fear of needle-based injections. This might make vaccination faster and easier to perform in large numbers of individuals, especially in settings where conventional injections are tougher to deliver.”
Professor Saul Faust from the University of Southampton, the trial’s chief investigator, said within the press release that “Viruses like Influenza, Coronaviruses and the Ebola group are evolving repeatedly and by the point vaccines are rolled out, they could be poorly matched – the present ‘reactive’ vaccine system struggles to maintain pace.”
“This recent class of universal vaccines are future-proofed. They not only protect against many variants concurrently, but potentially against related viruses that haven’t yet emerged and spilt over to humans,” Faust said.
The press release also states that “a bigger Phase two trial will next assess the vaccine’s ability to induce immune responses in a wider and more diverse population, and make sure that it generates strong, broadly protective immune responses.”
© 2026 Global News, a division of Corus Entertainment Inc.